Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding
08 Mayo 2024 - 9:00AM
Derm-Biome Pharmaceuticals, Inc, a Vancouver based
biopharmaceutical company focused on skin health and healthy aging,
is pleased to announce that, in partnership with TransBIOtech
(Quebec), is being awarded an Applied Research and Development
(ARD) grant via the College and Community Innovation (CCI) program
administered through the Natural Sciences and Engineering Council
of Canada in collaboration with the Social Sciences and Humanities
Research Council and the Canadian Institutes of Health Research.
Derm-Biome has developed novel compounds with wide ranging
pharmacological activities. The grant, which spans 3 years and
totals $450,000, will support Derm-Biome’s preclinical research
activities, with a focus on inflammatory diseases and healthy
aging.
Frédéric Couture, Principal Investigator and
Head of Pharmaceutical
Sciences at TransBIOtech: “This is very exciting
news. We are happy to pursue this collaboration with Derm-Biome and
help them propel their pipeline closer to new treatments. I believe
that, along with co-PIs Dr Sarah Paris-Robidas and Dr Carole-Ann
Huppé, our expertise in preclinical pharmacology in synergy with
Derm-Biome’s scientific team will accelerate future efficacy
validation of their products and provide them with the key
demonstrations needed for upcoming clinical trial
applications.”
Derm-Biome CEO Gordon Eberwein: “We are very pleased to have
been awarded this Applied Research and Development grant and very
much look forward to our continued working relationship with
TransBIOtech in helping advance our exciting preclinical
pipeline.”
About Derm-Biome Pharmaceuticals, Inc
Derm-Biome Pharmaceuticals, Inc. is a preclinical
biopharmaceutical company dedicated to improving skin health and
healthy aging. We are developing novel topical therapies for
inflammatory skin diseases and precancerous skin
conditions/non-melanoma skin cancers that are both highly effective
and well tolerated by skin.
ContactInvestor Inquiries:Gordon
Eberweingeberwein@derm-biome.comhttps://derm-biomepharmaceuticals.com/